These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 31227365

  • 1. Synthesis and in vitro cytotoxicity evaluation of β-carboline-combretastatin carboxamides as apoptosis inducing agents: DNA intercalation and topoisomerase-II inhibition.
    Jadala C, Sathish M, Reddy TS, Reddy VG, Tokala R, Bhargava SK, Shankaraiah N, Nagesh N, Kamal A.
    Bioorg Med Chem; 2019 Aug 01; 27(15):3285-3298. PubMed ID: 31227365
    [Abstract] [Full Text] [Related]

  • 2. Development of β-carboline-benzothiazole hybrids via carboxamide formation as cytotoxic agents: DNA intercalative topoisomerase IIα inhibition and apoptosis induction.
    Tokala R, Mahajan S, Kiranmai G, Sigalapalli DK, Sana S, John SE, Nagesh N, Shankaraiah N.
    Bioorg Chem; 2021 Jan 01; 106():104481. PubMed ID: 33261848
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of thiadiazolo-carboxamide bridged β-carboline-indole hybrids: DNA intercalative topo-IIα inhibition with promising antiproliferative activity.
    Tokala R, Sana S, Lakshmi UJ, Sankarana P, Sigalapalli DK, Gadewal N, Kode J, Shankaraiah N.
    Bioorg Chem; 2020 Dec 01; 105():104357. PubMed ID: 33091673
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH, Metwaly AM, Belal A, Mehany ABM, Ayyad RR, El-Adl K, Mahdy HA, Taghour MS, El-Gamal KMA, El-Sawah ME, Elmetwally SA, Elhendawy MA, Radwan MM, ElSohly MA.
    Arch Pharm (Weinheim); 2019 Nov 01; 352(11):e1900123. PubMed ID: 31463953
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM, Khalil AK, Mohamed MM, Eissa IH, El-Naggar AM.
    Bioorg Chem; 2020 Nov 01; 104():104255. PubMed ID: 32927130
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biological evaluation of imidazopyridinyl-1,3,4-oxadiazole conjugates as apoptosis inducers and topoisomerase IIα inhibitors.
    Subba Rao AV, Vishnu Vardhan MV, Subba Reddy NV, Srinivasa Reddy T, Shaik SP, Bagul C, Kamal A.
    Bioorg Chem; 2016 Dec 01; 69():7-19. PubMed ID: 27656775
    [Abstract] [Full Text] [Related]

  • 9. One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
    Shankaraiah N, Kumar NP, Amula SB, Nekkanti S, Jeengar MK, Naidu VG, Reddy TS, Kamal A.
    Bioorg Med Chem Lett; 2015 Oct 01; 25(19):4239-44. PubMed ID: 26292628
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design and synthesis of dithiocarbamate linked β-carboline derivatives: DNA topoisomerase II inhibition with DNA binding and apoptosis inducing ability.
    Kamal A, Sathish M, Nayak VL, Srinivasulu V, Kavitha B, Tangella Y, Thummuri D, Bagul C, Shankaraiah N, Nagesh N.
    Bioorg Med Chem; 2015 Sep 01; 23(17):5511-26. PubMed ID: 26264845
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K, El-Helby AA, Sakr H, Elwan A.
    Bioorg Chem; 2020 Dec 01; 105():104399. PubMed ID: 33113414
    [Abstract] [Full Text] [Related]

  • 17. Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors.
    Alesawy MS, Al-Karmalawy AA, Elkaeed EB, Alswah M, Belal A, Taghour MS, Eissa IH.
    Arch Pharm (Weinheim); 2021 Mar 01; 354(3):e2000237. PubMed ID: 33226150
    [Abstract] [Full Text] [Related]

  • 18. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
    Zhao W, Chen L, Li HM, Wang DJ, Li DS, Chen T, Yuan ZP, Tang YJ.
    Bioorg Med Chem; 2014 Jun 01; 22(11):2998-3007. PubMed ID: 24775914
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK, Taghour MS, Metwaly AM, Belal A, Mehany ABM, Elhendawy MA, Radwan MM, Yassin AM, El-Deeb NM, Hafez EE, ElSohly MA, Eissa IH.
    Eur J Med Chem; 2018 Jul 15; 155():117-134. PubMed ID: 29885574
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT, Woo H, Jeong HM, Khadka DB, Yang SH, Zhao C, Jin Y, Lee ES, Youl Lee K, Kwon Y, Cho WJ.
    Eur J Med Chem; 2014 Jul 23; 82():181-94. PubMed ID: 24904965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.